This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1985;254(13):1791-1794.

Abstract
Soft-tissue sarcomas and osteosarcomas are relatively rare tumors that represent less than 2% of all new adult cancer cases occurring each year in the United States. The number of new soft-tissue sarcomas and osteosarcomas diagnosed yearly is 4,800 and 1,900, respectively. Clinical advances in the treatment of these tumors are hampered by the difficulty of accruing adequate numbers of patients in valid prospective therapeutic trials.

Surgical resection has always had a major role in the treatment of the primary lesion in adult patients with either soft-tissue sarcoma or osteosarcoma of the extremities. Amputation of an extremity has been a relatively frequent choice of resection for soft-tissue sarcomas in the past because of high local treatment failure rates when wide surgical margins could not be achieved by a limb-sparing resection as the only treatment. For osteosarcomas in the extremities of both young and older adults, amputation has been the mainstay of treatment of the primary extremity lesion in most patients. The recognition of the possible role of radiation therapy and/or regional or systemic chemotherapy in the treatment of both soft-tissue sarcomas and osteosarcomas has raised many questions regarding the preoperative evaluation, extent of surgical resection required when these modalities are employed, the results of this treatment in comparison with amputation, and the optimal treatment strategy.

In an effort to resolve some of the questions surrounding these issues, the National Institutes of Health convened a Consensus Development Conference on Limb-Sparing Treatment of Adult Soft-Tissue and Osteosarcomas from Dec 3 to 5, 1984. During 1 1/2 days, presentations were made by experts in the field who reported their experience with the management of over 2,000 patients with high-grade extremity sarcomas. A consensus panel drawn from the medical professions and the general public considered the evidence and agreed on answers to the following key questions:

1. What is the optimal pretreatment evaluation of the high-grade sarcoma patient regarding diagnosis, extent of disease workup, and staging?
   
2. Are there types of patients for whom limb-sparing treatment should be considered appropriate therapy?
   
3. If so, what is the optimal limb-sparing treatment strategy? (Consider the following: indications and contraindications, extent of surgical resection, need for and form of radiation therapy and/or chemotherapy, treatment morbidity and function of the limb, and end results.)
   
4. Are there types of extremity sarcoma patients for whom adjuvant chemotherapy is indicated?
   
5. What directions should be taken for future research on the treatment of extremity sarcomas?
   

Footnotes
From the Office of Medical Applications of Research, National Institutes of Health, Bethesda, Md.

Reprint requests to Office of Medical Applications of Research, National Institutes of Health, Bldg 1, Room 216, Bethesda, MD 20205 (Michael J. Bernstein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Function and Health Status Outcomes in a Randomized Trial Comparing Preoperative and Postoperative Radiotherapy in Extremity Soft Tissue Sarcoma
Davis et al.
JCO 2002;20:4472-4477.
ABSTRACT | FULL TEXT  

Long-term Outcome in 87 Patients With Low-Grade Soft-Tissue Sarcoma
Marcus et al.
Arch Surg 1993;128:1336-1343.
ABSTRACT  

Limb Salvage Surgery for Sarcomas: A Good Idea Receives Formal Blessing
Benjamin
JAMA 1985;254:1795-1796.
ABSTRACT